SORD as a Radioligand Therapy Target
SORD, sorbitol dehydrogenase, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, SORD staining is highest in prostate cancer (100% of samples positive), thyroid cancer (100% of samples positive) and endometrial cancer (92% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is SORD a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in prostate cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
SORD expression in cancer
Protein expression of SORD across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Prostate Cancer | 1.00 | High | 100% |
| Thyroid Cancer | 0.67 | High | 100% |
| Endometrial Cancer | 0.67 | High | 92% |
| Colorectal Cancer | 0.61 | High | 91% |
| Breast Cancer | 0.53 | High | 83% |
| Cervical Cancer | 0.30 | Medium | 64% |
| Ovarian Cancer | 0.24 | Medium | 36% |
| Neuroendocrine Tumors | 0.17 | Low | 25% |
| Liver Cancer | 0.12 | Low | 36% |
| Melanoma | 0.10 | Low | 30% |
| Skin Cancer | 0.09 | Low | 27% |
| Bladder Cancer | 0.06 | Low | 18% |
| Glioma | 0.06 | Low | 18% |
| Pancreatic Cancer | 0.03 | Low | 9% |
Not detected by IHC in: head and neck cancer, lymphoma, kidney cancer, lung cancer, gastric cancer, testicular cancer.
Is SORD internalized?
Nuclens has not yet extracted internalization evidence for SORD. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
SORD clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for SORD yet. Search ClinicalTrials.gov for SORD trials.
SORD normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See SORD in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
SORD gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: 0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related prostate cancer radioligand targets
PSMA (FOLH1) · HER3 (ERBB3) · c-MET (MET) · EGFR · EPCAM · FAP · B7-H3 (CD276) · STEAP2
See all radioligand therapy targets in prostate cancer.
See how SORD ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.